A RETROSPECTIVE OBSERVATIONAL STUDY OF INTRAVITREAL OZURDEX IMPLANT IN TREATING MACULAR PERSISTEN EDEMA

This is an automatically generated default intro template – please do not edit.

	Read full article
Article Title:	A RETROSPECTIVE OBSERVATIONAL STUDY OF INTRAVITREAL OZURDEX IMPLANT IN TREATING MACULAR PERSISTEN EDEMA
Authors:	CRISTIAN TURLEA1,MAGDALENA TURLEA1,ILEANA ZOLOG4, PAVEL FARCAS2, ANDREI BRANCO TOMESCU3
Affiliation:	1Department of Ophthalmology ,West University”Vasile Goldis” Arad 2The Faculty of Economics, West University”Vasile Goldis” Arad 3Department of General Surgery, West University”Vasile Goldis” Arad 4Department of Ophthalmology ,University of Medicine and Pharmacy”Victor Babes” Timsioara
Abstract:	This retrospective study evaluates the efficacy of intravitreal implant with dexamethasone (Ozurdex®; Allergan Inc, Irvine, CA, USA) in the treatment of patients with persistent macular edema of different etiology. We evaluated 13 eyes of 13 patients who where diagnosed with macular edema of different aetiology and treated with a single intravitreal implant of Ozurdex with a follow-up of six months. The effects of the intravitreal implant where evaluated by best correction visual acuity(BCVA), central macular thickness(CMT) during a follow-up of 6 months. The mean baseline BCVA and standard deviation(STD) was 0,25±0,19 and after 6 months it was 0,60±0,24. The mean baseline CMT evaluated by optical coeherence tomography(OCT) was 556±145μ and after 6 months it decreased to a value of 275±68μ. There where no serious side effects, but for a temporary raise of intraocular pressure(IOP) in 4 patients,who responded to topical antihipertensive eyedrops and 2 patients who developed cataract. Intravitreal implants with Ozurdex have proven significant improvement in BCVA and CMT in patients with macular edema in a period of six months without any serious sight threatening events.
Keywords:	Inravitreal implant,Macular edema,Ozurdex,dexamethasone
References:	Haller JA, Bandello F, Belfort R Jr, et al; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–46 Kuppermann BD, Chou C, Weinberg DV, Whitcup SM, Haller JA, Blumenkranz MS; Dexamethasone DDS Phase II Study Group. Intravitreous dexamethasone effects on different patterns of diabetic macular edema. Arch Ophthalmol. 2010;128(5): 642–643) Mark C. Gillies, MBBS, PhD, Lyndell L. Lim, MBBS, Anna Campain, PhD,1 Godfrey J. Quin, MBChB, PhD,Wedad Salem, MB BS, MPH, Ji Li, MB BS, Stephanie Goodwin, BAppSc (Orthoptics) (Hons),Christine Aroney, MBBS, Ian L. McAllister, MBBS, Samantha Fraser-Bell, MBBS, PhD, A Randomized Clinical Trial of Intravitreal Bevacizumab versus Intravitreal Dexamethasone for Diabetic Macular Edema The BEVORDEX Study. Ophthalmology 2014;121:2473-2481 Rogers S, McIntosh RL, Cheung N, et al: The prevalence and number of people with retinal vein occlusion: pooled data from population-based studies from the US, Europe, Australia and Asia. Ophthalmology 2010;117:313–319.e1 Shamsi HNA, Masaud JS, Ghazi NG. Diabetic macular edema:New promising therapies. World J Diabetes 2013; 4(6): 324:338 Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004; 111: 2044-2049 Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010;304:649–56 Zucchiatti I, Lattanzio R, Queques G, et al. Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica. 2012;228:117–122
*Correspondence:	dr.turlea@gmail.com